A first-in-human, dose escalation and dose expansion study of SAR445877 in adult participants with advanced solid tumors

Trial Identifier: TCD17620
Sponsor: Sanofi
Start Date: November 2022
Primary Completion Date: January 2027
Study Completion Date: June 2028
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CHILE Providencia, CHILE, 7500000
CHILE, General Bernardo O'Higgins Rancagua, General Bernardo O'Higgins, CHILE, 2852424
CHILE, Reg Metropolitana de Santiago Santiago, Reg Metropolitana de Santiago, CHILE, 8420383
CHILE, Reg Metropolitana de Santiago Santiago, Reg Metropolitana de Santiago, CHILE, 8331143
ISRAEL Ramat Gan, ISRAEL, 5262100
ISRAEL Tel Aviv, ISRAEL, 6423906
ISRAEL Tzrifin, ISRAEL, 7033001
ISRAEL, Yerushalayim Jerusalem, Yerushalayim, ISRAEL, 9112001
JAPAN, Chiba Kashiwa, Chiba, JAPAN, 277-8577
NETHERLANDS, Noord-Holland Amsterdam, Noord-Holland, NETHERLANDS, 1066 CX
NETHERLANDS, Zuid-Holland Rotterdam, Zuid-Holland, NETHERLANDS, 3015 CE
SPAIN, Barcelona [Barcelona] Barcelona, Barcelona [Barcelona], SPAIN, 08035
SPAIN, Madrid Madrid, SPAIN, 28050
UNITED STATES, Delaware Newark, Delaware, UNITED STATES, 19718
UNITED STATES, Iowa Iowa City, Iowa, UNITED STATES, 52242
UNITED STATES, Kansas Westwood, Kansas, UNITED STATES, 66205
UNITED STATES, Michigan Detroit, Michigan, UNITED STATES, 48201
UNITED STATES, New Jersey Hackensack, New Jersey, UNITED STATES, 07601
UNITED STATES, New York New York, UNITED STATES, 10016
UNITED STATES, Rhode Island Providence, Rhode Island, UNITED STATES, 02905
UNITED STATES, Texas Houston, Texas, UNITED STATES, 77030
UNITED STATES, Washington Seattle, Washington, UNITED STATES, 98109